Articles related to CLINICAL TRIALS

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.

New data suggests that the Galleri blood test’s sensitivity for early-stage cancers may be lower than initially reported, potentially limiting its utility as a screening tool.

The FDA advisory committee’s decision highlights the complexities of perioperative treatment in NSCLC and the need for more precise efficacy data to guide clinical decision-making.

A phase 3 clinical trial of buntanetap in early Parkinson’s disease patients demonstrated improvements in motor and cognitive functions, particularly in those with longer disease duration and postural instability.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.